Literature DB >> 33211573

Imaging Features of Neurofibromatosis Type 1 in the Abdomen and Pelvis.

Maria Zulfiqar1, Michael Lin1, Kristy Ratkowski1, Marie-Helene Gagnon1, Christine Menias2, Cary Lynn Siegel1.   

Abstract

OBJECTIVE. Loss of the neurofibromatosis type 1 (NF1) tumor suppressor protein causes uninhibited activation of the RAS oncogene, which leads to tumorigenesis in patients with NF1. This case-based review discusses imaging manifestations of NF1 in the abdomen and pelvis, highlighting key genetic associations and management to elucidate features different from the general population. CONCLUSION. The spectrum of pathologic findings includes gastrointestinal tumors such as gastrointestinal stromal tumors, genitourinary lesions including urogenital neurofibromas, vascular entities such as renal artery stenosis, and less common associations like lymphoma.

Entities:  

Keywords:  lymphoma; malignant peripheral nerve sheath tumor; neurofibroma; neurofibromatosis type 1; paraganglioma; pheochromocytoma; renal artery stenosis

Mesh:

Year:  2020        PMID: 33211573     DOI: 10.2214/AJR.19.22283

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Adrenocortical carcinoma in a patient with neurofibromatosis type 1: A case report.

Authors:  Mohammad Najafi-Semnani; Mahdieh Rajabi-Moghaddam; Hamid Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2021

2.  Radiologic screening and surveillance in hereditary cancers.

Authors:  Jamie E Clarke; Stephanie Magoon; Irman Forghani; Francesco Alessandrino; Gina D'Amato; Emily Jonczak; Ty K Subhawong
Journal:  Eur J Radiol Open       Date:  2022-04-25

3.  A case report of mesenteric involvement in neurofibromatosis type 1.

Authors:  Nguyen Van Sang; Tran Phan Ninh; Dang Trung Thanh; Nguyen Cuong Thinh
Journal:  J Clin Imaging Sci       Date:  2022-07-29

Review 4.  [Imaging of tumor predisposition syndromes].

Authors:  K Glutig; A Pfeil; D M Renz
Journal:  Radiologe       Date:  2021-06-25       Impact factor: 0.635

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.